Notably, serplulimab, another anti-PD-1 agent, received approval from the NMPA in 2022 for its synergistic role with first-line chemotherapy in ES-SCLC, following the auspicious outcomes of the phase III ASTRUM-005 clinical trial (NCT04063163) [55]. Here, PDCD1 is linked to small cell lung carcinoma.